Medline Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MDLN in the last 7 days.
The FDA issued a Class I recall for certain Medline convenience kits with B. Braun components, which contain recalled Huons Bupivacaine Hydrochloride. B. Braun reported 35 serious injuries, while Medline reported none. The recall is effective as of June 19, according to the FDA.
GIC Private Ltd sold 1,600,000 shares of Medline Inc. (MDLN) at $35.80 ($57.28M total) across 2 trades over 2026-08-13 to 2026-08-14. Filed jointly with GIC Special Investments Pte Ltd (10% owner) and Hux Investment Pte. Ltd. (10% owner).
Kessler Topaz Meltzer & Check said it is investigating potential federal securities-law violations by Medline Inc. (NASDAQ: MDLN) after an FDA warning letter cited significant Current Good Manufacturing Practice violations, including failures to investigate discrepancies and microbial contamination. Reuters reported it was the second action in two months. Medline shares fell over 7% and then over 12% after Q2 results and lowered full-year adjusted EBITDA guidance.
Recent MDLN coverage spans regulation, insider activity and market movers.
In the last 30 days, MDLN insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($158.3M). The most active reporter was GIC Private Ltd with 6 filings.
The FDA issued a Class I recall for certain Medline convenience kits with B. Braun components, which contain recalled Huons Bupivacaine Hydrochloride. B. Braun reported 35 serious injuries, while Medline reported none. The recall is effective as of June 19, according to the FDA.
The filing is a large insider sale by a 10% owner, which can modestly pressure sentiment but is not a fundamental change by itself.
FDA warning-letter allegations around manufacturing quality and microbial contamination raise regulatory and operational risk for Medline.
Medline reported Q2 sales up 11.6% to $7.685B and net income down 58.3% to $139M, citing $336M fire-related losses tied to its Tracy, California distribution center. For 1H 2026, sales rose 11.1% to $15.037B. Medline said it signed over $650M in new customer business and is adding distribution centers, automation, and workers, including California capacity expansion to about 5M sq ft by mid-2027.
Raised organic sales outlook but tempered adjusted EBITDA outlook due to multiple headwinds, keeping margin risk central for MDLN.
alphai scores every news story that mentions MDLN with an AI model for sentiment and relevance, and aggregates insider trades from Medline Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA issued a Class I recall for certain Medline convenience kits with B. Braun components, which contain recalled Huons Bupivacaine Hydrochloride. B. Braun reported 35 serious injuries, while Medline reported none. The recall is effective as of June 19, according to the FDA.
1 min readGIC Private Ltd sold 1,600,000 shares of Medline Inc. (MDLN) at $35.80 ($57.28M total) across 2 trades over 2026-08-13 to 2026-08-14. Filed jointly with GIC Special Investments Pte Ltd (10% owner) and Hux Investment Pte. Ltd. (10% owner).
2 min readKessler Topaz Meltzer & Check said it is investigating potential federal securities-law violations by Medline Inc. (NASDAQ: MDLN) after an FDA warning letter cited significant Current Good Manufacturing Practice violations, including failures to investigate discrepancies and microbial contamination. Reuters reported it was the second action in two months. Medline shares fell over 7% and then over 12% after Q2 results and lowered full-year adjusted EBITDA guidance.
3 min readMedline reported Q2 sales up 11.6% to $7.685B and net income down 58.3% to $139M, citing $336M fire-related losses tied to its Tracy, California distribution center. For 1H 2026, sales rose 11.1% to $15.037B. Medline said it signed over $650M in new customer business and is adding distribution centers, automation, and workers, including California capacity expansion to about 5M sq ft by mid-2027.
6 min readMedline (MDLN) Q2 2026 call said adjusted EBITDA rose 13% YoY to $1.1B, with higher costs partly offset by a $243M IEEPA tariff refund benefit. Q2 net sales grew 12% to $7.7B. Company raised fiscal 2026 organic sales outlook, but moderated adjusted EBITDA outlook citing Middle East conflict, Tracy warehouse fire, investments, quality remediation, and retail softness.
7 min readMedline Inc. (NASDAQ: MDLN) received an FDA warning letter dated May 28, 2026 citing significant Current Good Manufacturing Practice violations, including inadequate investigation of batch discrepancies and microbial contamination, and poor cleaning practices, according to the FDA and Reuters. After the FDA news, MDLN shares fell over 7%. On Aug. 5, the stock dropped over 12% after Q2 results and lowered full-year adjusted EBITDA guidance.
4 min readKaplan Fox said the FDA issued a May 28, 2026 warning letter to Medline (NASDAQ: MDLN) citing significant Current Good Manufacturing Practice violations, including failures to investigate unexplained batch discrepancies and microbial contamination incidents. Reuters reported it was the second FDA action in two months. Medline shares fell $2.56, or 7.16%, to $33.19 on June 2, 2026.
3 min readMedline said regulatory guidance followed its corrective actions for surgical convenience kits whose components were affected by a Becton Dickinson recall. The alert cites BD lot 4032183 ChloraPrep Clear 1 mL and lot 4073005 FREPP Clear 1.5 mL applicators, with compromised sterile seals and possible Aspergillus contamination. Medline reported no severe injuries or deaths as of Aug 3. MDLN shares were $35.71, up 0.61%.
4 min readKaplan Fox said the FDA issued a May 28, 2026 warning letter to Medline (NASDAQ: MDLN) citing significant Current Good Manufacturing Practice violations, including failures to investigate unexplained batch discrepancies and microbial contamination incidents. Reuters reported it was the second FDA action in two months. Medline shares fell $2.56, or 7.16%, to close at $33.19 on June 2, 2026.
4 min readGIC Private Ltd sold 590,284 shares of Medline Inc. (MDLN) at $35.58 ($21.00M total) on 2026-08-07.
2 min read
